AWARE-1 data analyzed showing Pelareorep priming of TMETo understand the complex tumor microenvironment (TME) and immune responses in patients before and after treatment, we used imaging mass cytometry (IMC) to perform single cell, highly multiplexed, analysis of their tissue samples.
In accordance with the prior AWARE-1 results, IMC demonstrated an enhanced immune state of the tumors after treatment.
Results confirm previous data from the window of opportunity AWARE-1 study demonstrating synergy between pelareorep in combination with atezolizumab, and a favorable immunologic response in tumors from early breast cancer (eBC) patients.
https://jitc.bmj.com/content/11/Suppl_1/662